IMMUNITYBIO, INC. Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
IMMUNITYBIO, INC. (IBRX) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss of $13.00 thousand as of 2024-03-31, per its 10-Q filed 2024-05-09.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss · last filed 2025-03-03
- 2024-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $13.00K.
- 2023-12-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $49.00K.
- 2023-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $58.00K.
- 2023-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss $60.00K.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss |
|---|---|
| 2024-03-31 | $13.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $49.00K 10-K · filed 2025-03-03 |
| 2023-09-30 | $58.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $60.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $58.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-19 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 |
| 2022-06-30 | $50.00K 10-Q · filed 2022-08-08 |
| 2022-03-31 | $328.00K 10-Q · filed 2022-05-10 |
| 2021-12-31 | $37.00K 10-K · filed 2023-03-01 |
| 2021-09-30 | $2.00K 10-Q · filed 2021-11-12 |
| 2021-03-31 | $4.00K 10-Q · filed 2021-05-14 |
| 2020-12-31 | $19.00K 10-K · filed 2022-03-01 |
| 2020-09-30 | $16.00K 10-Q · filed 2020-11-09 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-07 |
| 2020-03-31 | $30.00K 10-Q · filed 2020-05-11 |
| 2019-12-31 | $3.00K 8-K/A · filed 2021-04-22 |
| 2019-09-30 | $2.00K 10-Q · filed 2019-11-05 |
| 2019-06-30 | $1.00K 10-Q · filed 2019-08-06 |
| 2019-03-31 | $11.00K 10-Q · filed 2019-05-08 |
| 2018-12-31 | $26.00K 10-K · filed 2020-03-25 |
| 2018-09-30 | $44.00K 10-Q · filed 2018-11-07 |
| 2018-06-30 | $277.00K 10-Q · filed 2018-08-06 |
| 2017-12-31 | $124.00K 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |